Research from the University of Birmingham shows that brain scans combined with machine learning analysis can identify mental health patients likely to have a poor outcome, which researchers hope will help clinicians target treatments more effectively.
Solid tumors carrying ATM gene alterations and BRCA1/2 defects had durable and prolonged responses when treated with the oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib (Bayer) according to a phase 1b trial presented at AACR this week.
Scientists from the University of California (UC), San Diego, and their collaborators have demonstrated how key proteins act together to suppress antitumor activity in high-grade serous ovarian carcinoma (HGSOC) in a mouse model, revealing a new combinatorial strategy to treat this intractable malignancy.
Read the April Inside Precision Magazine in its digital edition format. Get the latest news and information in precision medicine, molecular diagnostics, and more.
News & Features
Editas Announces First-Ever Pediatric In Vivo CRISPR Gene Editing Medicine Administration
Prior to the start of pediatric testing of EDIT-101, Editas had completed dosing of all adult cohorts in its BRILLIANCE study. The clinical results from this arm of the trial demonstrated a favorable safety profile and encouraging signals of clinical benefit.
An engineered bacterial strain developed by MIT scientists can allow treatment with antibiotics for infections, while also protecting 'friendly' gut bacteria, show results from a mouse study.
Some recurrent ductal carcinoma in situ breast tumors are new primary lesions, unrelated to the original cancer, according to a new sequencing-based study.
Two research groups performed single-cell RNA sequencing (scRNA-seq) of immune cells and combined the data with fine mapping of autoimmune disease–associated genetic variants to provide a resource that allows the large-scale identification of genotype-phenotype interactions.
The complexity of cancer can only be better understood and treated with a complex array of tools. In one case, cancer scientists use a single approach—circulating tumor DNA (ctDNA)—in many ways. Plus, even more uses of ctDNA lie ahead.
The terms minimal residual disease, measurable residual disease, and molecular residual disease, interchangeably referred to as MRD, denote what is left after cancer treatment with curative intent. Originally used to monitor patients with hematologic malignancies, MRD is becoming increasingly important in the field of solid tumor oncology because of its correlation with disease outcomes.